BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32899497)

  • 1. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
    Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
    Wang H; Shore EM; Pignolo RJ; Kaplan FS
    Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of G
    Ebner JK; König GM; Kostenis E; Siegert P; Aktories K; Orth JHC
    Bone; 2019 Oct; 127():592-601. PubMed ID: 31376533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
    Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
    J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.
    Le VQ; Wharton KA
    Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
    Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
    J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively active ALK2 receptor mutants require type II receptor cooperation.
    Bagarova J; Vonner AJ; Armstrong KA; Börgermann J; Lai CS; Deng DY; Beppu H; Alfano I; Filippakopoulos P; Morrell NW; Bullock AN; Knaus P; Mishina Y; Yu PB
    Mol Cell Biol; 2013 Jun; 33(12):2413-24. PubMed ID: 23572558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
    Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
    Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
    Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
    Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
    Lin H; Shi F; Gao J; Hua P
    Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
    Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.
    de Gorter DJ; Jankipersadsing V; Ten Dijke P
    Curr Pharm Des; 2012; 18(27):4087-92. PubMed ID: 22630080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in drug development for fibrodysplasia ossificans progressiva.
    Meng X; Wang H; Hao J
    Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
    Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
    J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
    Katagiri T; Tsukamoto S; Kuratani M
    Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.